Incidence and Visual Outcomes of Endophthalmitis After Intravitreal Injection of Dexamethasone Implant vs Ranibizumab.
| Autor: | Pancholy M; Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, PA, USA.; Department of Ophthalmology, Emory University, Atlanta, GA, USA., Storey PP; Austin Retina Associates, University of Texas Dell Medical School, Austin, TX, USA., Wood EH; Department of Ophthalmology, Stanford University, Stanford, CA, USA., Chaudhary V; McMaster University, Hamilton, ON, Canada., Obeid A; Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, PA, USA., Marlow E; Bay Area Retina Associates, Oakland, CA, USA., Farley ND; Associated Retinal Consultants, Oakland University William Beaumont School of Medicine, Royal Oak, MI, USA., Wolfe JD; Associated Retinal Consultants, Oakland University William Beaumont School of Medicine, Royal Oak, MI, USA., Garg SJ; Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, PA, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of vitreoretinal diseases [J Vitreoretin Dis] 2022 Aug 25; Vol. 6 (5), pp. 358-366. Date of Electronic Publication: 2022 Aug 25 (Print Publication: 2022). |
| DOI: | 10.1177/24741264221109376 |
| Abstrakt: | Purpose: To compare the incidence and visual outcomes of endophthalmitis after injection of an intravitreal dexamethasone implant and injection of intravitreal ranibizumab. Methods: This retrospective cohort study assessed endophthalmitis in eyes receiving an intravitreal injection of a 0.7 mg dexamethasone implant (DEX group), 0.5 mg ranibizumab (R5 group), or 0.3 mg ranibizumab (R3 group) between January 1, 2016, and May 31, 2018, at 2 large retina practices in the United States. Results: Suspected endophthalmitis occurred in 5 eyes after 4973 DEX injections, 43 eyes after 163 974 R5 injections, and 6 eyes after 18 954 R3 injections. Suspected endophthalmitis was significantly more common in the DEX group (1/995) than in the R5 group (1/3813) ( P = .008) but not than in the R3 group (1/3159) ( P = .10). Visual acuity outcomes were similar in the 3 groups. Conclusions: Suspected endophthalmitis might be more common after 0.7 mg dexamethasone injections than after 0.5 mg ranibizumab injections. Culture-positive endophthalmitis rates were similar across all 3 medications. Competing Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: All authors declare no support from any organization for the submitted work. Dr Jeremy Wolfe receives research support and consulting fees from Allergan and Genentech and is on the speakers’ bureau for these entities. Dr Varun Chaudhary receives grants and personal fees from Novartis and Bayer as well as personal fees from Roche and Alcon. Dr Marlow reports consulting fees from Regeneron and Novartis. Dr Garg receives grants from Genentech, Regeneron, Apellis, and Boehringer Ingelheim and consulting fees from Deciphera, Bausch & Lomb, Allergan, Kanaph, Boehringer Ingelheim, and Apellis. All other authors have no proprietary interests to disclose. (© The Author(s) 2022.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|